Shopping Cart
Remove All
Your shopping cart is currently empty
PD-L1/Nampt-IN-1 is an orally active inhibitor that targets both PD-L1 and NAMPT (nicotinamide phosphoribosyltransferase), with IC50 values of 63 nM and 582 nM, respectively. It exhibits cross-species affinity, with KD values of 52.6 nM for hPD-L1 and 49.1 nM for mPD-L1. This compound effectively suppresses tumor growth by activating the tumor immune microenvironment and is applicable in melanoma research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | PD-L1/Nampt-IN-1 is an orally active inhibitor that targets both PD-L1 and NAMPT (nicotinamide phosphoribosyltransferase), with IC50 values of 63 nM and 582 nM, respectively. It exhibits cross-species affinity, with KD values of 52.6 nM for hPD-L1 and 49.1 nM for mPD-L1. This compound effectively suppresses tumor growth by activating the tumor immune microenvironment and is applicable in melanoma research. |
| In vitro | PD-L1/Nampt-IN-1 (Compound T8) (0.5-5 μM) inhibits the interaction between PD-1 and PD-L1 in a dose-dependent manner, achieving an inhibition rate of 76.3% at a concentration of 5 μM. |
| In vivo | PD-L1/Nampt-IN-1 (Compound T8) administered orally at 50 mg/kg for 14 days significantly enhances tumor growth inhibition in the B16-F10 murine tumor model, attributed to the activation of the tumor immune microenvironment. In tumors, the compound accumulates at 1133.6 ng/mL at 8 hours and crosses the blood-brain barrier with 81.86 ng/mL at 1 hour. |
| Molecular Weight | 452.55 |
| Formula | C28H28N4O2 |
| Cas No. | 3054043-85-2 |
| Smiles | O=C(NCCNCC=1C=CC(=NC1OC)C=2C=CC=C(C=3C=CC=CC3)C2C)C=4C=NC=CC4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.